← 返回目录 05 · Risk Matrix 机密

MODE 1: Pre-Acquisition Deep Analysis (收购前深度分析)

Section 5: Risk Matrix (风险矩阵)

Project Tengen | IASO Bio × Medisix Therapeutics Date: 2026-03-20 | Classification: CONFIDENTIAL

5.1 Comprehensive Risk Matrix (综合风险矩阵)

Risk Scoring Methodology

STRATEGIC RISKS (战略风险)

# Risk Prob Impact Score Justification Mitigation Strategy Residual Risk Owner
S1 PEBL platform fails to extend beyond CD7 — CD99, CD70 expansion targets fail in preclinical/clinical 3 5 15 🔴 Platform extensibility is the primary value driver; CD99 expert-validated but no in vivo data yet; broader platform patent claims have support vulnerabilities [TiPLab] (1) Begin CD99 preclinical immediately post-closing with Campana; (2) Parallel CD70 evaluation; (3) Structure deal with earnout tied to platform expansion milestones Medium — dependent on biology; cannot fully mitigate CSO / R&D
S2 Wugen achieves FDA approval first — captures market with allogeneic off-the-shelf CD7 CAR-T; commoditizes CD7 indication 4 3 12 🟡 Wugen BLA target 2027; BTD + RMAT + Fast Track + PRIME designations; $115M raised; pivotal trial enrolling [Public data] (1) Differentiate on safety profile (PEBL: 0% Grade 3+ CRS vs Wugen's safety issues); (2) Focus on EMA CMA pathway (different regulatory); (3) Pivot value thesis to CD99/CD70 where Wugen has no presence Medium — competitive risk is structural BD / Strategy
S3 HK IPO timing conflict — Medisix acquisition complicates IASO's 2026 IPO timeline or narrative 2 3 6 🟢 IPO is strategic pillar #5; acquisition adds pipeline narrative but also integrates risk; Morgan Stanley/CCB International already advising (1) Frame acquisition as pipeline expansion (positive narrative); (2) Time closing to align with IPO preparation; (3) Ring-fence Medisix liabilities from IASO's IPO disclosures Low CFO / Investment Bank
S4 CD7 CAR-T has weak commercial value — Expert consensus that T-ALL patient pool too small for commercial viability 4 3 12 🟡 Dr. Pan Jing: "CD7 product has NO commercial value"; ~100 new T-ALL cases/year in China; must bridge to transplant [附件2] (1) Price deal based on platform, not CD7 alone; (2) CD7 serves as proof-of-concept for platform; (3) Focus commercial thesis on CD99/CD70 broader markets Medium — CD7 is proof-of-concept, not revenue driver BD / Commercial

FINANCIAL RISKS (财务风险)

# Risk Prob Impact Score Justification Mitigation Strategy Residual Risk Owner
F1 CPN conversion triggers excessive cost — $29M+ in CPNs with 85-95% discount and 2x cash return cap at $22M on Deemed Liquidation Event 5 4 20 🔴 CPNs mature Mar 31, 2026; acquisition = Deemed Liquidation Event; multiple tranches with different conversion mechanics [EY FDD, ArrowGates] (1) Pre-close negotiation with all note holders; (2) Leverage Medisix's distress (no alternative = haircut); (3) Offer note holders equity in combined entity or structured payout; (4) Include CPN resolution as closing condition Medium — note holders have leverage but alternatives are worse (liquidation → $0) CFO / Legal
F2 Total deal cost exceeds budget — Liability cleanup + manufacturing rebuild + integration > $100M 3 4 12 🟡 Base estimate $55-93M all-in; significant unknowns in asset valuation report (not readable), NUS renegotiation, and manufacturing costs (1) Cap upfront consideration; (2) Structure 40-60% as earnout/milestone; (3) Phase manufacturing investment over 24 months; (4) Build contingency reserve ($10M) Medium CFO
F3 Transfer pricing audit — SG/US tax authorities challenge $12M intercompany loan and 7% R&D markup 3 3 9 🟢 ArrowGates flagged: loan not covered by TP report; 7% at bottom of arm's length range (median 13.25%); retroactive change from 10% (1) Capitalize loan before closing; (2) Prepare contemporaneous TP documentation; (3) Engage Big 4 for Advance Pricing Arrangement if needed Low-Medium — addressable with proper structuring Tax / Legal
F4 FX exposure — SGD/USD/EUR/CNY volatility on deal payments and ongoing operations 3 2 6 🟢 Multi-currency exposure: acquisition in USD, operations in SGD/EUR, IASO in CNY; clinical costs at OPBG in EUR (1) FX hedging for known commitments; (2) Natural hedge through SG entity revenue/cost matching; (3) CNY-denominated earnout where possible Low Treasury

OPERATIONAL RISKS (运营风险)

# Risk Prob Impact Score Justification Mitigation Strategy Residual Risk Owner
O1 Manufacturing chain collapse — WuXi MSA expired; Lonza terminated; no plasmid stock; OPBG academic-only 4 5 20 🔴 WuXi retains process IP (OXGENET); BIOSECURE Act risk; Lonza Prodigy FAILED (3 batches); plasmid stock depleted; G-Rex semi-open manual process [CMC DD, ArrowGates] (1) Transfer construct to IASO LVV platform (Nanjing GMP); (2) Engage alternative CDMO (Samsung, Catalent) as backup; (3) Budget $10-15M and 18-24 months for full rebuild; (4) Maintain WuXi ad-hoc for stability testing during transition Medium-High — 18-24 month clinical gap risk CMC / Operations
O2 BIOSECURE Act disrupts WuXi relationship — WuXi named/proposed for DoD 1260H list; US government restrictions on grants/procurement 3 4 12 🟡 BIOSECURE signed Dec 2025 NDAA; WuXi proposed for 1260H; 5-year transition for listed entities; WuXi retains proprietary data [Public data, ArrowGates] (1) Accelerate WuXi exit — insource to IASO; (2) Document all WuXi deliverables before transition; (3) Negotiate data/DMF access from WuXi; (4) BIOSECURE primarily affects US operations — IASO's China base less impacted Medium — insourcing timeline is the risk CMC / Legal
O3 Key person loss — Campana departs — Scientific founder loses interest or has conflict with acquirer culture/management 3 5 15 🔴 Campana is sole inventor of PEBL; NUS professor (cannot be poached); personal AML patent not transferred; consulting agreement is personal services [Founder Agreement] (1) Retention package: $1-2M + milestone payments + academic freedom; (2) SAB appointment with meaningful role; (3) Resolve AML patent transfer before closing; (4) Engage NUS to support transition Medium — Campana's academic independence is both asset and risk HR / CEO
O4 OPBG clinical program stalls — Enrollment delays, regulatory issues, or Locatelli disengagement 2 4 8 🟢 11 patients enrolled of 23 target; multi-center expansion not yet initiated; OPBG retains data ownership (Clause 7.1) [附件3, ArrowGates] (1) Clinical collaboration agreement with OPBG; (2) Co-fund multi-center expansion; (3) Negotiate data access rights; (4) Parallel US IND preparation as alternative regulatory path Low-Medium Clinical / Regulatory
O5 Single point of failure — Cecilia Sim — Only person managing finance, HR, IT, legal for Medisix SG entity 4 3 12 🟡 No backup for any corporate function; no signed IP assignment agreement [ArrowGates] (1) IASO integration team shadow Cecilia from Day 1; (2) Retention bonus; (3) Knowledge transfer plan with 6-month overlap; (4) Secure IP assignment before closing Low — addressable with proactive transition Integration / HR

REGULATORY RISKS (监管风险)

# Risk Prob Impact Score Justification Mitigation Strategy Residual Risk Owner
R1 NUS license termination or adverse renegotiation — NUS leverages acquisition to extract unfavorable terms; or performance milestone (Aug 2027 regulatory submission) missed 2 5 10 🟡 NUS retains IP ownership; Amendments 3-4 under negotiation; equity participation up to 10%/$10M; sublicense sharing up to 40% [NUS License, ArrowGates] (1) Complete Amendment 3 before closing (closing condition); (2) Extend Aug 2027 milestone; (3) Cap equity participation; (4) Develop proprietary next-gen PEBL variants; (5) Build direct IASO-NUS relationship Medium — NUS dependency is structural Legal / BD
R2 EMA rejects CMA pathway — Sample size insufficient; LVV change requires new clinical data; PIP/ODD delays 2 4 8 🟢 EMA scientific advice obtained but conditional; LVV vs RVV separate products; PIP not filed [附件4, 附件9] (1) Prioritize 23-patient enrollment; (2) File PIP and ODD immediately; (3) Apply for PRIME; (4) Parallel US IND as alternative Low-Medium Regulatory
R3 NMPA does not approve PCART7 pathway — Bridging studies required; NMPA won't approve CAR-T + HSCT combination; endpoint mismatch 3 3 9 🟢 NMPA requires CR/CRi primary endpoint; does not approve combination products; European data may not be accepted directly [附件1, Prof. Lu Meng] (1) Plan China-specific clinical strategy; (2) Consider PCART7 monotherapy arm; (3) Leverage IASO's NMPA regulatory experience; (4) Focus initial China strategy on CD99/CD70 with broader market Low-Medium Regulatory
R4 GDPR data transfer compliance failure — OPBG patient data cannot be transferred to China without proper legal basis 3 3 9 🟢 No Data Processing Agreements or SCCs found in data room; China has no GDPR adequacy decision (1) Implement Standard Contractual Clauses; (2) Data minimization — process in EU, transfer only aggregated/anonymized; (3) Engage EU privacy counsel Low Legal / Data Protection

GEOPOLITICAL RISKS (地缘政治风险)

# Risk Prob Impact Score Justification Mitigation Strategy Residual Risk Owner
G1 SG-CN corridor restrictions tighten — Singapore introduces restrictions on Chinese biotech acquisitions in response to US/EU pressure 1 5 5 🟢 Singapore currently has open investment policy; Temasek/ClavystBio are existing Medisix investors (SG government-linked); no current restrictions (1) Maintain SG entity operating independently; (2) Engage SG government stakeholders early; (3) Preserve SG jobs and operations Low Government Relations
G2 US-CN tech decoupling affects clinical collaboration — US/EU restrictions on clinical data sharing with Chinese entities 2 3 6 🟢 Current focus on biosecurity (BIOSECURE) not clinical data; OPBG is Italian (not US); NUS is Singaporean (1) Structure data flows through SG/EU entities; (2) Maintain SG as data hub; (3) Monitor regulatory developments Low Legal / Compliance
G3 Sanctions screening failure — Transaction parties or beneficial owners on sanctions lists 1 5 5 🟢 Standard M&A diligence item; no red flags identified in data room (1) Full OFAC/EU/UN sanctions screening pre-close; (2) Screen all beneficial owners of note holders Low Compliance

INTEGRATION RISKS (整合风险)

# Risk Prob Impact Score Justification Mitigation Strategy Residual Risk Owner
I1 Manufacturing process transfer takes >24 months — LVV rebuild, process validation, and bridging studies extend beyond plan 3 4 12 🟡 JW Therapeutics precedent: adherent-to-suspension LVV change required 12 bridging cases; no plasmid stock; must rebuild from scratch [CMC DD] (1) Start process development Day 1; (2) Parallel tracks (IASO in-house + alternative CDMO); (3) Maintain OPBG academic supply for ongoing trial; (4) Budget 30-month timeline as contingency Medium CMC / Operations
I2 Cultural integration failure — Academic/SG culture clashes with IASO's aggressive commercial CN culture 3 3 9 🟢 Medisix has academic DNA (NUS/OPBG); IASO is commercially-driven; key stakeholders (Campana, Locatelli) are academics (1) Standalone entity model for SG/EU operations; (2) Preserve academic collaboration ethos; (3) Dedicated integration manager with cross-cultural experience Low-Medium HR / Integration
I3 JTC lease approval delayed or denied — Singapore government landlord blocks change of control 2 3 6 🟢 JTC change of control clause requires prior written consent; JTC is government agency with policy considerations [JTC Tenancy] (1) Early JTC engagement; (2) Emphasize continued SG operations and employment; (3) Alternative lab space if needed (small footprint — SGD 2.2K/month) Low Operations / Legal
I4 Anti-monopoly review required — SAMR/CCCS filing obligation or extended review 1 3 3 🟢 Small target (zero revenue, 4 employees); no market overlap in T-cell malignancies; IASO is in BCMA, Medisix in CD7 — complementary, not competitive (1) Assess filing thresholds (likely below); (2) Prepare filing if required; (3) No competition concerns expected Very Low Legal

5.2 Risk Heat Map (风险热力图)

IMPACT →
           1-Negligible  2-Minor  3-Moderate  4-Major  5-Catastrophic
          ┌──────────┬─────────┬──────────┬─────────┬──────────────┐
5-Certain │          │         │          │  F1(20) │              │
          ├──────────┼─────────┼──────────┼─────────┼──────────────┤
4-Likely  │          │         │ S4(12)   │ O1(20)  │              │
          │          │         │ S2(12)   │ O2(12)  │              │
          │          │         │ O5(12)   │         │              │
          ├──────────┼─────────┼──────────┼─────────┼──────────────┤
3-Possible│          │  F4(6)  │ F3(9)    │ F2(12)  │ S1(15)       │
          │          │         │ R3(9)    │ I1(12)  │ O3(15)       │
          │          │         │ R4(9)    │         │              │
          │          │         │ I2(9)    │         │              │
          ├──────────┼─────────┼──────────┼─────────┼──────────────┤
2-Unlikely│          │         │ S3(6)    │ R2(8)   │ R1(10)       │
          │          │         │ G2(6)    │ O4(8)   │              │
          │          │         │ I3(6)    │         │              │
          ├──────────┼─────────┼──────────┼─────────┼──────────────┤
1-Remote  │          │         │ I4(3)    │         │ G1(5)        │
          │          │         │          │         │ G3(5)        │
          └──────────┴─────────┴──────────┴─────────┴──────────────┘
P
R                    GREEN              YELLOW        RED
O                    (Score 1-4)        (Score 5-14)  (Score 15-25)
B
→

5.3 Risk Priority Summary (风险优先级汇总)

🔴 CRITICAL RISKS (Score ≥ 15) — Require pre-closing resolution

Risk Score Key Action
F1: CPN conversion cost 20 Negotiate restructuring with all note holders before closing
O1: Manufacturing chain collapse 20 Budget $10-15M and plan 18-24 month rebuild; leverage IASO infrastructure
S1: PEBL platform extension failure 15 Structure deal with platform expansion earnout; begin CD99 preclinical immediately
O3: Campana departure 15 Secure retention package and IP transfer before closing

🟡 HIGH RISKS (Score 10-14) — Require active management

Risk Score Key Action
S2: Wugen competition 12 Differentiate on safety; pivot to CD99/CD70
S4: CD7 weak commercial value 12 Price for platform, not CD7
F2: Total cost overrun 12 Cap upfront; structure earnout
O2: BIOSECURE/WuXi 12 Accelerate insourcing
O5: Cecilia Sim SPOF 12 Knowledge transfer from Day 1
R1: NUS license risk 10 Complete Amendment 3 before closing
I1: Manufacturing delay 12 Parallel tracks; 30-month contingency

🟢 MODERATE/LOW RISKS (Score < 10) — Monitor

All remaining risks (S3, F3, F4, R2, R3, R4, G1, G2, G3, O4, I2, I3, I4) — standard monitoring sufficient.

[All source citations refer to documents indexed in 00_Document_Inventory.md]

← 04 战略逻辑与协同分析 06 交易结构建议 →